New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
0
5

Psoriatic Arthritis and the Heart: Is There a Risk?

Study finds many commonalities, but no evidence of excess mortality.  
medpagetoday.com
almost 6 years ago
Preview
0
5

Researchers find gene that confirms existence of psoriatic arthritis

PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage.  
medicalnewstoday.com
almost 6 years ago
Preview
0
7

Provectus Biopharmaceuticals begins recruitment for phase 2 mechanism of action clinical trial of PH-10 for psoriasis

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company ('Provectus'), has announced that it has opened recruitment for its phase 2 mechanism...  
medicalnewstoday.com
almost 6 years ago
Preview
0
3

Proteins identified that are likely to trigger psoriasis

Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world.  
medicalnewstoday.com
almost 6 years ago
Preview
0
7

FDA approves new psoriasis drug Cosentyx

The U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.  
medicalnewstoday.com
almost 6 years ago
Preview
0
6

Psoriasis: Otezla (apremilast), receives European marketing authorisation in two therapeutic indications

Celgene UK has announced that the European Commission has licensed Otezla, the Company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic...  
medicalnewstoday.com
almost 6 years ago
Preview
0
10

Review article estimates annual U.S. cost of psoriasis in 2013

The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by...  
medicalnewstoday.com
almost 6 years ago
Preview
0
4

US regulatory submission of the first aerosol foam for psoriasis

LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the...  
medicalnewstoday.com
almost 6 years ago
Preview
0
4

Results from Phase III study evaluating oral otezla or injectable etanercept versus placebo in patients with moderate to severe plaque psoriasis

Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4...  
medicalnewstoday.com
almost 6 years ago
Preview
0
5

New antibody therapy dramatically improves psoriasis symptoms in clinical trial

Only a single treatment produced what researchers describe as 'rapid, substantial, and durable clinical...  
medicalnewstoday.com
almost 6 years ago
Preview
0
6

Cosentyx (secukinumab) is the first IL-17A inhibitor to be available for moderate to severe plaque psoriasis in the UK

Novartis Pharmaceuticals UK Limited (Novartis) has announced that Cosentyx (secukinumab) is available for use in the UK for the treatment of moderate to severe plaque psoriasis in adults who...  
medicalnewstoday.com
almost 6 years ago
Preview
0
11

Marshaling the body's own weapons against psoriasis

Immunotherapy with natural signaling substance relieves skin conditionA three-character code brings relief to patients with psoriasis and sheds light on complex...  
medicalnewstoday.com
almost 6 years ago
Preview
0
11

First independent U.S. psoriasis registry to track drug safety and effectiveness

People with psoriasis and their health care providers will have the opportunity to participate in research that aims to improve treatments and disease outcomes when the first independent U.S.  
medicalnewstoday.com
almost 6 years ago
Preview
0
1

Boehringer Ingelheim's investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.  
medicalnewstoday.com
almost 6 years ago
Preview
0
17

NICE recommends Stelara (ustekinumab) for the treatment of active psoriatic arthritis

Janssen has announced that the National Institute for Health and Clinical Excellence (NICE), has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD)1 as...  
medicalnewstoday.com
almost 6 years ago
Preview
0
23

Oral Otezla (apremilast) long-term safety and efficacy data in patients with moderate to severe plaque psoriasis presented

Celgene Corporation has announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast) were presented at the 73rd...  
medicalnewstoday.com
almost 6 years ago
Www.bmj
0
16

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
feeds.bmj.com
almost 6 years ago
Www.bmj
1
11

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
bmj.com
almost 6 years ago
Www.bmj
1
13

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials

Objective To evaluate the relative risk of pulmonary disease among patients with psoriasis, psoriatic arthritis, and inflammatory bowel disease treated with methotrexate.  
bmj.com
almost 6 years ago